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termed PSC-IBD) are at increased risk for colorectal cancer, but their risk following a diagnosis
of low-grade dysplasia (LGD) is not well described. We aimed to determine the rate of advanced
colorectal neoplasia (aCRN), defined as high-grade dysplasia and/or colorectal cancer, following
a diagnosis of indefinite dysplasia or LGD in this population.METHODS: We performed a retrospective, longitudinal study of 1911 patients with colonic IBD (293 with
PSC and 1618 without PSC) who underwent more than 2 surveillance colonoscopies from 2000
through 2015 in The Netherlands or the United States (9265 patient-years of follow-up eval-
uation). We collected data on clinical and demographic features of patients, as well as data from
each surveillance colonoscopy and histologic report. For each surveillance colonoscopy, the
severity of active inflammation was documented. The primary outcome was a diagnosis of aCRN
during follow-up evaluation. We also investigated factors associated with aCRN in patients with
or without a prior diagnosis of indefinite dysplasia or LGD.RESULTS: Patients with PSC-IBD had a 2-fold higher risk of developing aCRN than patients with non-PSC
IBD. Mean inflammation scores did not differ significantly between patients with PSC-IBD
(0.55) vs patients with non-PSC IBD (0.56) (P [ .89), nor did proportions of patients with
LGD (21% of patients with PSC-IBD vs 18% of patients with non-PSC IBD) differ significantly
(P [ .37). However, the rate of aCRN following a diagnosis of LGD was significantly higher in
patients with PSC-IBD (8.4 per 100 patient-years) than patients with non-PSC IBD (3.0 per 100
patient-years; P [ .01). PSC (adjusted hazard ratio [aHR], 2.01; 95% CI, 1.09–3.71), increasing
age (aHR 1.03; 95% CI, 1.01–1.05), and active inflammation (aHR, 2.39; 95% CI, 1.63–3.49) were
independent risk factors for aCRN. Dysplasia was more often endoscopically invisible in pa-
tients with PSC-IBD than in patients with non-PSC IBD.hip.
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July 2018 Advanced Colorectal Neoplasia in PSC-IBD 1107CONCLUSIONS: In a longitudinal study of almost 2000 patients with colonic IBD, PSC remained a strong
independent risk factor for aCRN. Once LGD is detected, aCRN develops at a higher rate in
patients with PSC and is more often endoscopically invisible than in patients with only IBD. Our
findings support recommendations for careful annual colonoscopic surveillance for patients
with IBD and PSC, and consideration of colectomy once LGD is detected.Keywords: Surveillance; Colon Cancer; Crohn’s Disease; Ulcerative Colitis; Primary Sclerosing Cholangitis.Patients with inflammatory bowel disease (IBD)are at an increased risk of developing colorectal
cancer (CRC).1,2 The co-occurrence of primary scle-
rosing cholangitis (PSC),1,3 a chronic liver disease char-
acterized by progressive inflammation and fibrosis of
the bile ducts,4 increases this risk substantially.5
Although an estimated 70% of patients with PSC have
a concomitant diagnosis of IBD (termed PSC-IBD),6
only 3% to 5% of patients with IBD have concomitant
PSC, with the diagnosis more common in patients with
ulcerative colitis (UC).5,7 The PSC-IBD phenotype often
is characterized by extensive colitis with rectal-
sparing and backwash ileitis, albeit with a mild and
often asymptomatic clinical course.8–13 However,
despite their mild clinical colitis, patients with PSC-
IBD compared with patients with only IBD colitis have
a 3- to 5-fold higher risk of CRC, and the cancers occur
more often in the right colon.14,15 As such, current
guidelines recommend that patients with PSC-IBD be
enrolled in a CRC surveillance program with an annual
colonoscopy from the time of PSC diagnosis, regardless
of their duration of IBD. This is in contrast to patients
with IBD colitis and no PSC (non-PSC IBD), in which
CRC surveillance is recommended after 8 years of
colonic disease.5,16–18
The development of neoplasia in IBD colitis follows a
multistep sequence from chronic inflammation and no
dysplasia or indefinite dysplasia (IND) to low grade-
dysplasia (LGD) and high-grade dysplasia (HGD), before
final malignant transformation to adenocarcinoma. As
such, the presence and grade of dysplasia remain the
best current indicators of cancer risk in IBD. There is an
increasing tendency to keep patients with LGD on
intensive surveillance instead of recommending procto-
colectomy.19,20 However, very few studies have
described the risk of advanced colorectal neoplasia
(aCRN) in patients with PSC-IBD after a diagnosis of IND
and/or LGD.21,22 Furthermore, the studies that do report
on the risk of neoplasia in patients with PSC-IBD were
performed in an era in which imaging-enhanced endos-
copy and high-resolution endoscopy were not used
routinely.
The aims of the present study were to report on the
risk of aCRN in a well-characterized cohort of patients
with PSC-IBD enrolled in a surveillance program in the
modern endoscopic era, and to describe the rate of aCRN
after a diagnosis of IND and/or LGD in these patients
compared with patients with non-PSC IBD and long-
standing IBD colitis also undergoing surveillance.Methods
Study Population and Case Identification
Patients with established IBD colitis undergoing
colonoscopic surveillance between 2000 and 2015 were
identified retrospectively from 2 databases: a Dutch
database inclusive of 2 secondary and 6 tertiary centers
and the Mount Sinai Hospital database in New York City
inclusive of 1 tertiary IBD referral center. Cases were
identified by query of the electronic health record (EHR)-
linked database using both International Classification of
Diseases, 9th and 10th revision codes, and free text
searches for cases of IBD and also free text searches
for PSC.
Patient Selection: Inclusion and
Exclusion Criteria
After initial identification through the EHR query,
individual charts were reviewed. For patients with PSC-
IBD, a clinical diagnosis of PSC had to be confirmed by
distinctive features on cholangiography or liver biopsy
(for patients with small-duct PSC). Additional inclusion
criteria were as follows: (1) diagnosis of IBD (UC, CD, IBD
undifferentiated [IBD-U]) with colonic involvement
confirmed endoscopically and histologically; (2)
confirmed colonic disease duration of at least 8 years for
patients with non-PSC IBD or any colonic disease dura-
tion for patients with PSC-IBD; (3) enrollment in a sur-
veillance program; and (4) at least left-sided colitis (UC
or IBD-U) or involvement of more than 30% of the
colonic surface (CD or IBD-U). Patients with a history of
colectomy before enrollment or a history of aCRN before
or at the index colonoscopy during the defined study
period were excluded. Surveillance procedures were
defined as colonoscopies in which either segmental
random biopsies or chromoendoscopy were used. Colo-
noscopies with other indications (eg, medically re-
fractory disease), were excluded. The index colonoscopy
was defined as the first surveillance colonoscopy per-
formed within the study period (2000–2015).
Data Collection
Database coding was identical for all study pop-
ulations. The date of study entry was set at the first
surveillance colonoscopy in the database. The time of
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The date of the last colonoscopy was set as the last day of
follow-up evaluation.
The following baseline demographic and clinical data
were abstracted: date of birth, sex, date of PSC diagnosis
(if applicable), date of IBD diagnosis, IBD type, maximum
disease extent, and date of prior diagnosis of IND and/or
LGD (if applicable). Maximum disease extent was defined
as the maximum documented extent of endoscopic disease
on any colonoscopy and was coded as follows: extensive/
pancolitis (>50%) or intermediate/left-sided (30%–50%).
Medication exposure (at least 1 prescription) was recorded
for mesalamine, thiopurines, and biologics.
Data from each surveillance colonoscopy were
recorded, including date of examination, quality of bowel
preparation (adequate or inadequate), most proximal
extent examined, use of chromoendoscopy, presence and
severity of endoscopic inflammation, presence of post-
inflammatory polyps (pseudopolyps), stricture(s), and
visible lesions. Endoscopically detected neoplastic
lesions were categorized based on morphology (polypoid/
nonpolypoid). Endoscopically invisible neoplasia was
defined as neoplasia detected in a random biopsy with no
corresponding morphologic lesion seen on endoscopy.
Right-sided lesions were defined as those proximal to the
splenic flexure. Because this was a retrospective study,
there was no a priori protocol in place to record endo-
scopic activity in a uniform way. Thus, for each surveil-
lance colonoscopy, the severity of active endoscopic
inflammation was scored on a 4-point scale for each
colonic segment visualized to allow for standardization: 0,
no inflammation/remission; 1, mild inflammation; 2,
moderate inflammation; or 3, severe inflammation. A
mean inflammatory severity score per patient and per
colonoscopy was calculated by dividing the sum of in-
flammatory severity scores by the total number of colonic
segments visualized per colonoscopy and then by the total
number of surveillance colonoscopies.Histology
Dysplasia was recorded as IND, LGD, or HGD. All his-
tologic diagnoses were as reported in the original pa-
thology report; no specimens were re-reviewed or altered
for this study. Of note, it is routine clinical practice at each
participating institution that colorectal neoplasia is
reviewed at the time of diagnosis and agreed upon by at
least 2 pathologists.Primary and Secondary Outcomes
The primary outcome was a diagnosis of aCRN,
defined as HGD or CRC, during follow-up evaluation.
Secondary outcomes were a diagnosis of IND and/or LGD
during follow-up evaluation and the development of
aCRN after a diagnosis of IND and/or LGD. Factors
associated with a diagnosis of aCRN in patients withPSC-IBD or patients with non-PSC IBD with or without a
prior diagnosis of IND and/or LGD were explored.
Statistical Analysis
Basic descriptive statistics were generated for patients
meeting inclusion criteria. Chi-square and Fisher exact
tests were used to compare categoric variables and
dichotomous outcomes, whereas the Student t test and the
Mann–Whitney U test were used for analyzing continuous
data. Incidence rates were calculated as the number of
cases per 100 patient-years of follow-up evaluation. Uni-
variate and multivariate Cox-regression modeling was
used to identify factors associated with aCRN. The pro-
portional hazards assumption of time-static covariates
was assessed using log–log plots and Schoenfeld residuals.
Because inflammatory scores were not stable over time,
these were input as time-changing covariates into the
models. Mean inflammation scores were recalculated at
every time point for each patient to correct for the vari-
able number of colonoscopies. A P value of .10 or less was
used as the cut-off value for selecting variables for the
multivariate analysis. Kaplan–Meier survival curves were
generated to compare cumulative incidence rates. Follow-
up data were censored at the last point of colonoscopic
follow-up evaluation, aCRN diagnosis, or colectomy.
All data analyses were performed using SPSS version 22
(IBM Corp, Armonk, NY).
Study Oversight
The Institutional Review Board at each of the
included sites approved the creation and analysis of a
longitudinal retrospective cohort database of patients
with colonic IBD undergoing surveillance.
Results
Baseline Demographic and Clinical
Characteristics
Of 1911 patients with colonic IBD in the combined
database meeting inclusion criteria, 293 patients were
confirmed to have PSC-IBD; the remaining 1618 patients
with non-PSC IBD served as the comparison group
(Figure 1). The main demographic and clinical features of
the cohort are detailed in Table 1. Compared with the
non-PSC IBD group, patients with PSC-IBD were more
often male and younger at study entry, although the age
at IBD diagnosis was similar between groups (P ¼ .11).
As expected, UC was the predominant IBD type in the
PSC-IBD group. Patients with PSC-IBD were less
frequently exposed to IBD therapy compared with pa-
tients with non-PSC IBD. In 151 patients (51.5%), the
PSC diagnosis was established after the IBD diagnosis,
while in 36 patients (12.3%) PSC was established before
the IBD diagnosis. For the remainder, PSC and IBD were
Figure 1. Description of patient selection and main outcomes
in each database. NL, The Netherlands.







Male, % 205 (70.0%) 796 (49.2%) <.001
Age at study inclusion,
y, means (SD)
39 (14) 45 (13) <.001
IBD type <.001
Ulcerative colitis 203 (69.3%) 912 (56.4%)
Crohn’s colitis 76 (25.9%) 661 (40.9%)
Indeterminate colitis 14 (4.8%) 45 (2.8%)
Disease extent <.001
Not specified 34 (11.8%) 154 (9.6%)
Limited extent/proctitis 13 (4.5%) 49 (3.1%)
Intermediate/left-sided 41 (14.2%) 572 (35.8%)
Extensive/pancolitis 201 (69.6%) 823 (51.5%)
Age at IBD diagnosis,
y, mean (SD)
27 (13) 28 (12) .11
IBD duration, y, mean (SD) 12 (10) 17 (9) <.001
Age at PSC diagnosis,
y, mean (SD)
32 (14) - -
Medication use
Mesalamine 221 (75.4%) 1316 (81.3%) .02
Thiopurines 93 (31.7%) 825 (51.0%) <.001
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diagnoses was not recorded.
The mean follow-up period for the total cohort was
4.8 years (SD, 3.0 y), with a total of 9265 patient-years
of follow-up evaluation; there was no difference in
follow-up time between patients with PSC-IBD and pa-
tients with non-PSC IBD. The number of surveillance
colonoscopies performed within the study period was
higher in patients with PSC-IBD compared with patients
with non-PSC IBD (3.8 vs 3.3; P < .01).
Inflammatory Activity
The endoscopic severity of inflammation on surveil-
lance examinations was similar between patients with
PSC-IBD and patients with non-PSC IBD (Supplementary
Table 1). The proportion of procedures in which exten-
sive active disease was observed in patients with PSC-
IBD vs patients with non-PSC IBD patients was 27% vs
12% (P < .01), 23% vs 10% (P < .01), and 27% vs 10%
(P < .01) for the first, second, and third surveillance
colonoscopy, respectively. The proportion of patients in
endoscopic remission on each of their surveillance
colonoscopies during the entire study period was higher
in patients with non-PSC IBD compared with patients
with PSC-IBD (P ¼ .02).
Occurrence of Advanced Colorectal Neoplasia
and Associated Risk Factors
Among patients with PSC-IBD, aCRN was diagnosed in
17 patients (5.8%), with CRC in 7 (2.4%) and HGD in 10
patients (3.4%) (Table 2). The frequency of aCRN during
follow-up evaluation was significantly lower in patients
with non-PSC IBD (2.9%), with CRC and HGD diagnosed
in 1.4% and 1.5% patients, respectively (P ¼ .01). The
incidence rate of aCRN in patients with PSC-IBD
compared with patients with non-PSC IBD was signifi-
cantly higher (1.3 vs 0.6/100 patient-years; P < .01)
(Figure 2). Although aCRN was more often right-sided in
patients with PSC-IBD compared with patients with non-
PSC IBD, this was not statistically significant (53% vs
31%; P ¼ .12). Among 40 patients with PSC-IBD (14%)
in whom the diagnosis of PSC was newly established
within the study period, 3 cases of aCRN occurred, with a
mean duration of 4.0 years (2.5 y) between the PSC
diagnosis and aCRN occurrence. The primary outcomes
stratified by study site are detailed in Supplementary
Table 2.
On multivariate Cox-regression analysis, PSC
(adjusted HR [aHR], 2.01; 95% CI, 1.09–3.71), increasing
age (aHR, 1.03; 95% CI, 1.01–1.05), and active inflam-
mation (aHR, 2.39; 95% CI, 1.63–3.49) remained inde-
pendent predictors of aCRN diagnosis during follow-up
evaluation (Table 3). Correcting for geography (United
States vs The Netherlands) did not affect these findings
(Supplementary Table 3).
Table 2. Description of the Outcomes During the Study Period
PSC-IBD (n ¼ 293) Non-PSC IBD (n ¼ 1618) P value
Advanced neoplasia (aCRN) 17 (5.8%) 47 (2.9%) .01
CRC 7 (2.4%) 22 (1.4%) .19
HGD 10 (3.4%) 25 (1.5%) .03
LGD, patients with 1 LGD lesion 60 (20.5%) 295 (18.2%) .37
IND, patients with IND as highest grade lesion 27 (9.2%) 74 (4.6%) .001
Time from IBD diagnosis to aCRN diagnosis, y, mean 19.4 24.3 .15
Time from database entry to aCRN diagnosis, y, mean 4.2 3.4 .31
Time from LGD to aCRN diagnosis, y, mean 0.7 1.7 .12
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Diagnosis of Indeterminate Dysplasia and/or
Low-Grade Dysplasia
The number of patients in the total cohort with at
least 1 diagnosis of IND was 147 (7.7%). In 101 patients
(5.3%) no additional dysplasia was detected. Among
patients with a diagnosis of IND, the rate of developing
aCRN after detection of IND was higher in patients
with PSC-IBD compared with patients with non-PSC IBD
(P ¼ .02) (Supplementary Figure 1). However, when
patients with a synchronous or metachronous diagnosis
of LGD (n ¼ 46) were excluded from this analysis (ie, no
grade of dysplasia higher than IND), this difference was
no longer significant.
The occurrence of at least 1 LGD-containing lesion
during the study period was similar for both patients
with PSC-IBD and patients with non-PSC IBD (21% vs
18%; P ¼ .37). Despite a similar proportion of patients
with LGD, the rate of developing aCRN after detection of
LGD was almost 3-fold higher in patients with PSC-IBD
compared with patients with non-PSC IBD (8.4 vs 3.0/
100 patient-years; P ¼ .01) (Figure 3).
For the subgroup of patients with LGD, the number of
patients in whom endoscopically invisible LGD wasFigure 2. Kaplan–Meier time-to-event (aCRN) analysis, all
patients since study entry.detected over the course of surveillance was higher in
patients with PSC-IBD (38% vs 22%; P ¼ .01). The
proportion of invisible LGD cases among the total num-
ber of LGD cases (per-colonoscopy analysis) also was
higher. In a subanalysis of The Netherlands population,
we corrected for the total number of random biopsy
specimens taken (107,745 biopsy specimens in total);
the number of random biopsy specimens needed to
detect invisible dysplasia was 826 in patients with PSC-
IBD compared with 1703 in patients with non-PSC IBD.
On univariate Cox regression analysis, only PSC and
multifocal dysplasia were associated with a higher risk of
aCRN diagnosis after LGD detection, whereas polypoid
morphology of the lesion (vs nonpolypoid or invisible)
was associated with a lower risk. On multivariate anal-
ysis, only polypoid morphology remained significant and
was associated with a reduced risk of aCRN (aHR, 0.31;
95% CI, 0.14–0.65) after LGD detection compared with
nonpolypoid or endoscopically invisible lesions
(Supplementary Table 4).
Discussion
In this large, multicenter, cross-national, longitudinal
cohort study of patients with confirmed IBD colitis un-
dergoing colonoscopic CRC surveillance, we report a
higher risk of aCRN in patients with concomitant PSC
compared with those without PSC, in the current era of
improved endoscopic technology and more effective
medical therapy for inflammation. Although these find-
ings corroborate previous studies, we further expand
knowledge in the field by reporting an even higher risk
of aCRN after detection of LGD (but not IND alone). That
LGD was endoscopically invisible more often in patients
with PSC-IBD compared with patients with non-PSC IBD
justifies the more intensive management considerations
for this population. Our findings suggest that although
continued meticulous CRC surveillance with annual co-
lonoscopy is indicated in the absence of dysplasia for
patients with PSC-IBD, the detection of LGD or higher-
grade pathology should lead to a careful weighting of
the pros and cons of more aggressive therapeutic man-
agement, including colectomy.
In our well-characterized surveillance cohort of pa-
tients with PSC-IBD undergoing surveillance, we found
Table 3. Univariate and Multivariate Cox-Regression Analysis for the Overall Risk of aCRN: All Patients
Variable
Univariate Multivariate
HR 95% CI P value aHR 95% CI P value
Age, y 1.02 1.01–1.04 .03 1.03 1.01–1.05 .007
Age at IBD diagnosis 1.00 0.98–1.02 .78
Sex, reference: male 1.83 1.08–3.08 .02 1.62 1.94–2.79 .08
PSC 2.13 1.22–3.70 .01 2.01 1.09–3.71 .03
Inflammation severity, mean (0–3)a 2.14 1.48–3.09 <.001 2.39 1.63–3.49 <.001
IBD type, reference: UC 0.99 0.60–1.61 .95
Maximum disease extent, reference: pancolitis 1.43 0.85–2.41 .18
Thiopurine exposure 0.84 0.51–1.40 .85
Biological exposure 0.72 0.36–1.46 .36
Mesalamine exposure 1.14 0.58–2.25 .70
Number of surveillance procedures 0.96 0.84–1.09 .53
aEntered as time-changing covariate; 0, no inflammation/remission; 1, mild; 2, moderate; 3, severe.
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risk of aCRN. This risk is slightly lower than prior studies
and a recent meta-analysis of 16 studies that reported a
3.4-fold higher odds for colorectal neoplasia in patients
with PSC-IBD.23 Importantly, the increased risk in our
study remained after correcting for active endoscopic
inflammation over time (which was used as a time-
changing covariate rather than a mean overall score).
Endoscopic activity assessed during subsequent colo-
noscopies was associated strongly with the risk of future
aCRN, congruent with studies in the population with
non-PSC IBD.24–26 Whether the outcomes of endoscopic
inflammation compared with histologic inflammation are
distinct remains a question for future investigation.
The increased risk of CRC in patients with PSC and
concomitant colonic IBD has firmly been established,
although the underlying mechanisms remain unclear.3,27–30
The nearly 3-fold higher rate of aCRN (HGD and/or CRC)
diagnosis after LGD detection, as well as the difference in
location, morphology, and endoscopic conspicuousness ofFigure 3. Kaplan–Meier time-to-event (aCRN) analysis,
patients with LGD only.dysplasia in patients with PSC-IBD compared with patients
with non-PSC IBD, suggests nuances in the pathogenesis of
neoplasia between these groups. Several investigators have
proposed a role for altered colonic bile composition in
carcinogenesis. A right-sided predominance of neoplasia
reinforces this hypothesis, as well as several studies directly
measuring the bile acid composition in both animals and
human beings.29,31,32 There is also evidence supporting the
notion that patients with PSC have an altered colonic
microbiome irrespective of concurrent IBD or ursodeox-
ycholic acid treatment.33 Still, whether these bacterial al-
terations are a cause or a consequence of the disease
characteristics specific to PSC remains to be clarified. Pa-
tients with PSC also share a distinct genotype,34 which may
predispose them further to neoplastic progression. More
likely, the underlying etiologies are multifactorial with roles
for gene–environment interactions, the microbiome, and
epigenetic modifications. Further investigations will hope-
fully open new avenues for novel therapeutic discovery and
primary and secondary prevention.
All told, because the mechanisms underlying PSC as an
independent risk factor for CRC in the setting of IBD colitis
are unclear, the best strategy for CRC prevention in pa-
tients with PSC-IBD remains frequent, attentive surveil-
lance colonoscopy. An important observation from our
study that distinguishes patients with PSC-IBD from pa-
tients with non-PSC IBD, is that dysplasia was detected
more often in random biopsies. Although previous retro-
spective studies have shown a low overall yield for
dysplasia with random biopsies as opposed to only tar-
geted biopsies of visible lesions, there was higher yield for
dysplasia on random biopsy in patients with concurrent
PSC.35,36 Our data further add to this body of evidence,
and it therefore can be questioned whether the current
recommendation, based on the results of prospective
studies, to move away from random biopsies as part of
CRC surveillance should apply to patients with PSC-
IBD.37,38 During surveillance examinations, particular
attention should be paid to the proximal colon because
right-sided cancers seem to be more common in patients
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colitis.32 Although the proportion of right-sided aCRNwas
higher in the PSC-IBD subgroup, this difference was not
statistically significant in the present study and may be
owing to insufficient power; it also may reflect selection
bias because one of our inclusion criteria for the non-PSC
IBD subgroup was at least left-sided disease extent or
more than 30% involvement, and thus may not represent
the overall IBD population. Our study confirms that the
date of PSC diagnosis is particularly relevant when risk-
stratifying patients because it seems that the risk of
neoplastic progression is highest within the first few years
of the PSC diagnosis.39 Thus, although CRC surveillance is
recommended after a disease duration of 8 years in pa-
tients with colonic IBD and no PSC,40 CRC surveillance at
the time of diagnosis in the setting of PSC is recommended
and further corroborated by our findings.
Our study had several strengths. In addition to being a
large IBD surveillance cohort in themodern era, our cohort
is particularly robust because each patient was confirmed
to have colonic IBD and to be actively enrolled in a colo-
noscopic CRC surveillance program. Comprehensive data
on disease history and endoscopic findings during sur-
veillance allowed for more accurate neoplastic risk
assessment, particularly with respect to measurement of
inflammatory burden over time. Importantly, detailed in-
formation on inflammatory activity at each colonoscopy
was incorporated into the analysis for more accurate
assessment of aCRNdevelopment in patientswithPSC-IBD.
Our study also had some limitations, most notably the
retrospective design. Despite the large size of our PSC-
IBD cohort, additional subanalyses, such as stratifica-
tion according to IBD type or medication use, yielded
insufficient power to permit meaningful conclusions.
Although we combined surveillance cohorts from 2
different countries, we predefined the inclusion/exclu-
sion criteria, variables to be assessed, and definitions of
outcomes. Combining these 2 cohorts enhanced not only
our power to detect meaningful differences, but also the
generalizability of our findings given that our study
population included patients from affiliated community-
based sites as well as tertiary IBD referral centers. That
said, there may be unmeasured differences in care
pathways between The Netherlands and the United
States, leading to heterogeneity in our study results. It is
important to note, however, that after adjusting for study
site and clinical–demographic differences between The
Netherlands and US cohorts, our results remained sig-
nificant (Supplementary Table 3). The lack of standard-
ized guidelines for the use of chromoendoscopy for CRC
surveillance in patients with IBD colitis unfortunately
precluded a meaningful analysis of its impact on
dysplasia detection because 10% or fewer examinations
were performed with chromoendoscopy. Finally,
although no samples were re-reviewed by pathologists
for the purposes of this study, it is routine practice at all
institutions participating in this study that whenever
there is a diagnosis of CRN, that the specimen isreviewed by 2 pathologists and consensus is reached
before final reporting.
In summary, using a large well-characterized cohort
of patients with confirmed colonic IBD undergoing sur-
veillance between 2000 and 2015, we substantiated
prior smaller reports of the increased risk of aCRN in
patients with concurrent PSC-IBD compared with pa-
tients with only IBD colitis undergoing surveillance.
Novel findings of our study include the significantly
higher rate of aCRN diagnosis after a diagnosis of LGD in
the setting of PSC complicating IBD. This finding together
with a higher risk of invisible dysplasia in patients with
PSC-IBD highlights the need for an ongoing strict CRC
surveillance program in these patients and a low
threshold to advise colectomy once LGD is detected in
this select population.
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Supplementary Figure 1. Kaplan–Meier time-to-event
(aCRN) analysis for patients with IND; time from first IND
within study interval to event (P ¼ .02, log-rank test). aCRN
was defined as CRC and/or HGD.
Supplementary Table 1. Inflammatory Parameters During Surveillance
PSC-IBD Non-PSC IBD P value
Severity of active inflammation, mean (0–3)a 0.55 0.56 .89
Extent of active inflammation, mean (0–3)a 1.36 1.17 .003
Activity ratio for all surveillance colonoscopies, active:inactive 45% 41% .19
No inflammation on all surveillance colonoscopies 76 (27.1%) 546 (34.1%) .02
Inflammation extent, first colonoscopy .001
No activity 127 (53.6%) 864 (57.9%)
Limited 7 (3.0%) 89 (6.0%)
Intermediate 38 (16.0%) 363 (24.3%)
Extensive/pancolitis 65 (27.4%) 176 (11.8%)
Inflammation extent, second colonoscopy <.001
No activity 125 (55.3%) 866 (61.2%)
Limited 9 (4.0%) 109 (7.7%)
Intermediate 40 (17.7%) 297 (21.0%)
Extensive/pancolitis 52 (23.0%) 141 (10.0%)
Inflammation extent, third colonoscopy <.001
No activity 102 (57.3%) 584 (63.6%)
Limited 6 (3.4%) 79 (8.6%)
Intermediate 22 (12.4%) 164 (17.9%)
Extensive/pancolitis 48 (27.0%) 92 (9.9%)
Endoscopic inflammation severity, first colonoscopy .20
No activity 160 (57.1%) 924 (57.8%)
Mild 100 (35.7%) 495 (30.9%)
Moderate 19 (6.8%) 131 (8.2%)
Severe 1 (0.4%) 50 (3.1%)
Endoscopic inflammation severity, second colonoscopy .77
No activity 125 (53.6%) 864 (59.3%)
Mild 89 (38.2%) 445 (30.5%)
Moderate 16 (6.9%) 101 (6.9%)
Severe 3 (1.3%) 48 (3.3%)
Endoscopic inflammation severity, third colonoscopy .17
No activity 102 (55.4%) 583 (61.6%)
Mild 63 (34.2%) 276 (29.2%)
Moderate 13 (7.1%) 64 (6.8%)
Severe 6 (3.3%) 23 (2.4%)
aCorrected for total number of surveillance colonoscopies per patient.
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Male 674 (53.1%) 327 (50.9%) .37
Age at study inclusion, means (SD) 45 (12) 41 (15) <.001
Age at IBD diagnosis, means (SD) 29 (12) 26 (14) <.001
PSC 171 (13.5%) 122 (19.0%) .002
Age at PSC diagnosis, means (SD) 33 (12) 32 (16) .37
IBD type <.001
Ulcerative colitis 800 (63.0%) 315 (49.1%)
Crohn’s colitis 434 (34.2%) 303 (47.2%)
Indeterminate colitis 35 (2.8%) 24 (3.7%)
Extensive disease/pancolitis 686 (54.1%) 338 (52.6%) .56
Medication use
Mesalamines 999 (78.7%) 543 (83.8%) .008
Thiopurines 556 (43.8%) 362 (56.4%) <.001
Biologicals 156 (12.3%) 284 (44.2%) <.001
Number of surveillance colonoscopies, means 3.4 3.3 .25
Interval between surveillance colonoscopies, y, means 1.6 1.2 <.001
Neoplasia outcomes
CRC 17 (1.3%) 12 (1.9%) .37
HGD 15 (1.2%) 20 (3.1%) .003
LGD 264 (20.8%) 88 (13.7%) <.001
Supplementary Table 3. Univariate and Multivariate Cox-Regression Analysis for the Overall Risk of aCRN (All Patients),
Corrected for Study Site
Variable
Univariate Multivariate
HR 95% CI P value aHR 95% CI P value
PSC 2.13 1.22–3.70 .008 1.85 1.00–3.43 .049
Inflammation severity (0–3)a 2.14 1.48–3.09 <.001 2.08 1.42–3.07 <.001
Sex (reference: male) 1.83 1.08–3.08 .02 1.68 0.97–2.89 .06
IBD type (reference: UC) 0.99 0.60–1.61 .95
Maximum disease extent (reference: pancolitis) 1.43 0.85–2.41 .18
Age at IBD diagnosis 1.00 0.98–1.02 .78
Age (years) 1.02 1.01–1.04 .03 1.03 1.01–1.05 .004
Thiopurine exposure 0.84 0.51–1.40 .85
Biological exposure 0.72 0.36–1.46 .36
5-aminosalicylate exposure 1.14 0.58–2.25 .70
Number of surveillance procedures 0.96 0.84–1.09 .53
Population (reference: US) 2.82 1.72–4.62 <.001 2.20 1.30–3.74 .003
NOTE. aCRN was defined as colorectal cancer and/or HGD.
aEntered as time-changing covariate; 0, no inflammation/remission; 1, mild; 2, moderate; 3, severe.
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Supplementary Table 4. Univariate and Multivariate Cox-Regression Analysis for the Risk of aCRN After Detection of LGD
Variable
Univariate Multivariate
HR 95% CI P value aHR 95% CI P value
PSC 2.52 1.19–5.31 .02 1.79 0.83–3.88 .14
Sex, reference: male 1.23 0.60–2.49 .57
Thiopurine exposure 1.20 0.60–2.40 .60
Biological exposure 0.74 0.23–2.44 .74
Mesalamine exposure 1.07 0.44–2.59 .88
Dysplasia characteristics
Distal location 1.69 0.77–4.32 .17
Multifocality 2.46 1.22–4.95 .01 1.90 0.93–3.87 .08
Polypoid morphology 0.27 0.13–0.57 .001 0.31 0.14–0.65 .002
Invisible dysplasia 1.64 0.76–3.53 .21
Nonpolypoid morphology 1.82 0.70–4.74 .22
NOTE. aCRN was defined as colorectal cancer and/or HGD.
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